Drug Profile
Ustekinumab biosimilar - Formycon
Alternative Names: FYB 202Latest Information Update: 06 Dec 2023
Price :
$50
*
At a glance
- Originator Formycon
- Developer Formycon; Fresenius Kabi; FYB202 GmbH & Co. KG
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Antiulcers; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 12 inhibitors; Interleukin 23 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Immunological disorders
- Phase III Plaque psoriasis